| Nov 5 |
Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock
|
| Nov 4 |
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
|
| Nov 4 |
Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?
|
| Oct 29 |
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
|
| Oct 10 |
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
|
| Oct 2 |
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability
|
| Sep 25 |
Heron gains on FDA nod for new Zynrelef application
|
| Sep 25 |
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
|
| Sep 11 |
Heron Therapeutics: Zynrelef Developments Are Unlikely To Provide Relief To Investors
|
| Sep 9 |
Exploring Three High Growth Tech Stocks in the United States
|
